A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis.

Trial Profile

A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2015

At a glance

  • Drugs Ibandronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms SUMMIT
  • Sponsors Roche
  • Most Recent Events

    • 01 Jul 2012 Results published in the Joint Bone Spine.
    • 21 Oct 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top